REICIN ALISE 4
4 · Sana Biotechnology, Inc. · Filed Jun 5, 2026
Research Summary
AI-generated summary of this filing
Sana (SANA) Director Reicin Alise Receives 90,000-Share Option Award
What Happened Reicin Alise, a director of Sana Biotechnology, received a derivative equity award on 2026-06-04 covering 90,000 shares. The filing shows a grant/award (code A) at $0.00 per share (no cash paid or exercised), so there was no immediate sale or purchase of stock.
Key Details
- Transaction date: 2026-06-04; Form 4 filed: 2026-06-05 (appears timely).
- Instrument: Derivative equity award (option/award) for 90,000 shares; reported price $0.00.
- Vesting: 100% vests on the earlier of (i) June 4, 2027 or (ii) immediately prior to the 2027 annual meeting, subject to continuous service (footnote F1).
- Shares owned after transaction: not specified in the supplied filing details.
- Exhibit included: Ex. 24 — Power of Attorney.
Context This was a grant of options/awards to a board member, a common form of director compensation. It is not an exercise or sale, so there was no immediate cash flow or change in free-float. The award’s future value depends on Sana’s stock performance and the vesting condition (continued service through the vest date).
Insider Transaction Report
Form 4
REICIN ALISE
Director
Transactions
- Award
Stock Option (Right to Buy)
[F1]2026-06-04+90,000→ 90,000 totalExercise: $2.96Exp: 2036-06-03→ Common Stock (90,000 underlying)
Footnotes (1)
- [F1]The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.
Signature
/s/ Aaron M. Grossman, Attorney-in-Fact for Alise Reicin|2026-06-05